Serum BAFF Concentrations in Patients with Graves' Disease and Orbitopathy before and after Immunosuppressive Therapy | Zendy

Guia Vannucchi | Zendy; Danila Covelli | Zendy; Nicola Currò | Zendy; Davide Dazzi | Zendy; Antonia Maffini | Zendy; Irene Campi | Zendy; P. Bonara | Zendy; Claudio Guastella | Zendy; Lorenzo Pignataro | Zendy; Roberto Ratiglia | Zendy; Paolo BeckPeccoz | Zendy; Mario Salvi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum BAFF Concentrations in Patients with Graves' Disease and Orbitopathy before and after Immunosuppressive Therapy

Author(s) -

Guia Vannucchi,

Danila Covelli,

Nicola Currò,

Davide Dazzi,

Antonia Maffini,

Irene Campi,

P. Bonara,

Claudio Guastella,

Lorenzo Pignataro,

Roberto Ratiglia,

Paolo BeckPeccoz,

Mario Salvi

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2614

Subject(s) - b cell activating factor , medicine , autoantibody , rheumatoid arthritis , immunology , antibody , rituximab , graves' disease , endocrinology , b cell , thyroid

B cells are known to play a key role in the pathogenesis of autoimmune disease. B lymphocyte activating factor (BAFF), a member of TNF family, promotes autoantibody production by increasing B cell survival and proliferation. Serum BAFF concentrations have been found to be increased in systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research